Trial Profile
A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Dalbavancin (Primary) ; Aztreonam; Cefadroxil; Clindamycin; Flucloxacillin; Metronidazole; Metronidazole; Oxacillin; Vancomycin
- Indications Bacterial infections; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie; Allergan; Durata Therapeutics
- 14 Apr 2024 This trial has been completed in Bulgaria, according to the European Clinical Trials Database record.
- 16 Jan 2024 Status changed from recruiting to completed.
- 04 Jul 2023 This trial has been discontinued in Spain, according to the European Clinical Trials Database record.